AI assistant
Sending…
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2023
Jun 22, 2023
32254_dirs_2023-06-22_40bdd420-ea17-42a7-827a-efbb14c55f46.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2023-06-20
Reporting Person: Landis John B. (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-06-20 | Stock Option (Right to Buy) | $3.26 | A | 26100.00 | Acquired | 2033-06-19 | Common Stock (26100.00) | Direct |
| 2023-06-20 | Stock Option (Right to Buy) | $3.50 | A | 13000.00 | Acquired | 2033-06-19 | Common Stock (13000.00) | Direct |
More from EyePoint Pharmaceuticals, Inc.
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 6
Regulatory Filings
2026
Apr 13
Director's Dealing
2026
Mar 24
Regulatory Filings
2026
Mar 20
Regulatory Filings
2026
Mar 4
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 18
Major Shareholding Notification
2026
Feb 12
Director's Dealing
2026
Jan 7